Preparing for commercialization?
Discuss commercial readiness, launch timing and organizational decisions with PharmaKonsult.
Insights Hub
Rare Disease Commercialization Insights
Why rare disease markets require different commercial models—Centers of Excellence, patient journeys and focused organization design.
Overview
Rare disease commercialization should not be treated as a smaller version of a traditional pharmaceutical launch. Diagnosis pathways, specialist concentration, advocacy networks and access complexity reshape the commercial model.
This hub connects PharmaKonsult perspectives on rare disease strategy with neuroscience and endocrinology commercialization experience.
